Compliance · The complete guide

ICH Q3B Impurities Drug Product

TL;DR

ICH Q3B(R2) governs degradation products in new drug PRODUCTS (finished form), as the companion to Q3A(R2) for drug substance. It sets three concentration thresholds — Reporting Threshold (RT), Identification Threshold (IT) and Qualification Threshold (QT) — each pegged to maximum daily dose (MDD). Below RT, list the impurity at its level. Above RT but below IT, report. Above IT, identify (structural elucidation). Above QT, qualify (toxicology + safety justification). Q3B applies only to degradation products formed in the drug product (during manufacture, storage, or use); process impurities arising from the API are governed by Q3A. Mutagenic impurities — anywhere in the drug product — are subject to the much tighter ICH M7 thresholds, which override Q3B for that class of impurity.

Reviewed May 25, 2026· By V5 Ultimate compliance team· 2,700 words · ~13 min read

01Q3B(R2) threshold table — keyed off max daily dose

MDD (g/day)	Reporting Threshold (RT)	Identification Threshold (IT)	Qualification Threshold (QT)
≤ 1 g	0.1% or 1 mg/day (whichever is lower)	0.2% or 2 mg/day intake (whichever is lower)	0.5% or 200 µg/day intake (whichever is lower)
> 1 g	0.05%	0.1%	0.15%

02RT / IT / QT — what each threshold demands

Reporting Threshold (RT) — every degradation product at or above this level appears in the batch record + CoA; below RT, not reported individually (but contributes to 'total degradants');
Identification Threshold (IT) — every impurity at or above IT must be structurally identified. Identification methods: LC-MS, NMR, IR, comparison to authentic standard. Unidentified degradants > IT are inspection-citation territory;
Qualification Threshold (QT) — every impurity at or above QT must be qualified. Qualification = demonstrated safety at the intended exposure level, typically by toxicology study, structural-similarity argument to a qualified parent, literature, or prior clinical/marketed exposure history;
'Total degradants' — sum of all degradants reported including unidentified peaks; a separate specification line typically applied.

03Qualification routes — how to clear an impurity above QT

Route	When applicable	Evidence required
Toxicology study at qualified level	Novel impurity above QT, no other route	In vivo + in vitro per ICH M3 / S2 panel; safety margin documented
Structural similarity to qualified parent	Impurity is a known metabolite or close structural analogue of API	SAR analysis + literature; sometimes acceptable without de novo tox
Prior clinical exposure	Impurity was present at the same or higher level in pivotal clinical batches	Cross-reference IND / NDA batch + clinical experience
Marketed product comparison	Impurity also present in approved comparator at same level	Pharmacopoeial / authentic-sample comparison
Literature	Published safety data sufficient to bridge	Critical literature review with regulatory justification

04ICH M7 mutagenic-impurity overlay — overrides Q3B

Mutagenic impurities (DNA-reactive — e.g. alkyl halides, epoxides, hydrazines, aldehydes, nitrosamines, certain heterocycles) are governed by ICH M7 regardless of Q3B threshold. The Threshold of Toxicological Concern (TTC) = 1.5 µg/day for daily lifetime exposure delivers a 10⁻⁵ excess cancer-risk safety standard. For shorter exposures (< 10 yr) higher LTLs are permitted per the Less-Than-Lifetime (LTL) staircase. Any degradation product with a structural alert (per (Q)SAR + expert review) is treated as Class 3 until proven otherwise. Nitrosamines — particularly NDMA / NDEA / NDIPA — have their own much tighter Acceptable Intake limits per ICH M7(R2) and EMA / FDA nitrosamine guidance.

05Stability-only impurities — degradants vs process impurities

A degradation product is one formed by chemical degradation of the API (or excipient) in the formulation, during storage, manufacture, or use;
Process impurities (synthesis-related) in the API are governed by Q3A, not Q3B — they must be controlled at the drug-substance stage and not double-counted;
Stability-indicating method (ICH Q2(R2) + ICH Q1A) is required to separate degradants from process impurities and matrix peaks;
Forced-degradation studies (acid, base, peroxide, light, heat, humidity) identify all potential degradants and inform stability-indicating method development;
Specification for degradants is set against the long-term + accelerated stability profile through the proposed shelf life, with safety margin at end-of-shelf-life.

06Interaction with ICH Q1A stability — shelf-life setting

Q3B + Q1A interact tightly. Stability studies generate the degradation profile across long-term + intermediate + accelerated conditions. The proposed shelf life must keep individual degradants below their specification (typically at or below QT unless qualified) and total degradants below the umbrella spec at end-of-shelf-life. Significant change at accelerated (typically 5% loss of assay, or a degradant exceeding specification) triggers intermediate testing + may force shelf-life shortening. The same degradation data feeds the Q3B 'identified / qualified' classification per the threshold table.

07Common failure modes

RT / IT / QT applied to drug substance instead of drug product (Q3A vs Q3B confusion).
MDD used incorrectly — peak daily dose for a chronic chronic-use product is the right MDD, not average. Acute / single-dose products handled per shorter-LTL framework when justified.
Mutagenic impurity treated under Q3B not M7 — single most-common 483 finding in this area.
Unidentified impurity > IT carried on CoA without identification effort — inspection citation.
Qualification by 'structural similarity' without rigorous SAR / toxicologist sign-off.
Specification set at QT for every degradant regardless of whether qualified — over-tight spec causes false OOS without scientific basis.
Stability-indicating method not actually separating degradants — co-elution missed; impurity level under-reported.
Total-degradants spec set high enough that individual identified+qualified peaks 'hide' an unidentified one.
Change in synthesis route or new excipient supplier introduces new degradant; not reassessed against Q3B/M7.
Photodegradation (Q1B) skipped; light-induced impurity discovered post-launch.

08How V5 Ultimate runs Q3B impurity control

Per-product impurity register: each identified degradant + RT/IT/QT classification + qualification status (qualified / qualified-by-route / pending) + qualifying evidence;
MDD-driven threshold calculator: RT/IT/QT updated automatically on label-change / dose-change;
M7 (Q)SAR pipeline: every degradant assessed by (Q)SAR + expert-review workflow; classification Class 1-5 + AI/LTL calculator;
Stability-indicating method linkage: method-validation evidence per Q2(R2) + forced-degradation report + peak-purity confirmation;
Per-batch CoA: degradant levels vs spec + RT/IT/QT classification rendered automatically;
Stability-study integration: long-term / accelerated / intermediate data feeds the Q3B classification + shelf-life setting;
Change-control hook: synthesis change / excipient change / packaging change auto-routes to impurity-profile reassessment;
Inspection pack: per-product impurity profile + qualification dossiers + stability + M7 (Q)SAR results — exports as one PDF.

Frequently asked questions

Q.What's the difference between Q3A and Q3B?+

Q3A governs process impurities in the drug SUBSTANCE (API). Q3B governs degradation products in the drug PRODUCT (formulation). Both use RT/IT/QT thresholds but with different scope and slightly different dose-keyed tables. Same impurity could be a process impurity under Q3A and never appear in Q3B if it does not increase on stability.

Q.What is qualification?+

Demonstrated safety of an impurity at the intended human exposure level. Routes include de novo toxicology study, structural similarity to a qualified parent, prior clinical exposure at the same level, or comparison to marketed comparator. The qualification rationale is a regulated dossier section.

Q.Does Q3B apply to biologics?+

No — biologics have their own degradation / impurity framework under ICH Q6B and product-specific guidances. Q3B is for new chemical entities + small-molecule generics.

Q.Are excipient-related impurities covered?+

Degradation products formed in the drug product from API-excipient interaction or excipient degradation are covered by Q3B. Excipient impurities present from the supplier (e.g. heavy metals in lactose) are covered by Q3D + USP excipient monographs.

Q.What about leachables from the container-closure?+

Leachables are governed by USP <1663>/<1664> + the E&L framework — separate from Q3B. However, an extractable that increases on stability and meets the definition of a degradation product can fall under both regimes; document explicitly.

Q.How do we handle excursion above QT mid-shelf-life?+

Investigation per OOS / OOT framework; if confirmed and the impurity is not qualified at the higher level, the affected stability stations are flagged + the proposed shelf-life is shortened, the change is reflected in the specification, and any commercial product already at higher level is recalled per impact assessment.